



**The Vall d'Hebron Institute of Oncology (VHIO) seeks a post-doctoral scientist to join our Applied Genetics of Metastatic Cancer Group.**

**Reference:** 01/2019

**Application deadline:** 15<sup>st</sup> February

**Number of vacancies:** 1

**Job description:**

We seek an enthusiastic and motivated post-doctoral scientist to join VHIO's Applied Genetics of Metastatic Cancer Group. The successful candidate will participate in exciting and ongoing projects, collaborating with other leading international research centers to identify driver genetic alterations in tumor tissue and liquid biopsies and better understand the mechanisms of genetic and tumour microenvironment heterogeneity in cancers.

**Requirements:** Applicants must have a PhD, a background in bioinformatics, and experience in next generation genomics and transcriptomics processing and analysis - preferably related to cancer biology. Fluency in English is mandatory.

**Additional information:** Applicants should hold a degree in bioinformatics and have previous experience and a track record in massively parallel sequencing data analysis.

**Application:** Please send your CV and cover letter highlighting your scientific interests using the form in our web page or via email to: [selecciorrh@vhio.net](mailto:selecciorrh@vhio.net), adding "Ref. 01/2019" in the subject line.

**About VHIO:**

Under the leadership of Josep Tabernero, the Vall d'Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer center of proven excellence internationally. It is thanks to Josep Tabernero's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.

Located within the Vall d'Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d'Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology

professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.

VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.

VHIO's translation toward precision oncology: <http://www.vhio.net>.